A detailed history of Black Rock Inc. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 2,344,007 shares of JANX stock, worth $133 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,344,007
Previous 1,693,991 38.37%
Holding current value
$133 Million
Previous $63.8 Million 53.96%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$35.12 - $64.78 $22.8 Million - $42.1 Million
650,016 Added 38.37%
2,344,007 $98.2 Million
Q1 2024

May 10, 2024

SELL
$7.93 - $49.75 $540,112 - $3.39 Million
-68,110 Reduced 3.87%
1,693,991 $63.8 Million
Q4 2023

Feb 13, 2024

BUY
$5.85 - $11.7 $716,753 - $1.43 Million
122,522 Added 7.47%
1,762,101 $18.9 Million
Q3 2023

Nov 13, 2023

BUY
$9.56 - $14.0 $4.25 Million - $6.23 Million
444,991 Added 37.25%
1,639,579 $16.5 Million
Q2 2023

Aug 11, 2023

BUY
$11.08 - $15.92 $664,168 - $954,292
59,943 Added 5.28%
1,194,588 $14.2 Million
Q1 2023

May 12, 2023

BUY
$11.25 - $22.21 $355,387 - $701,613
31,590 Added 2.86%
1,134,645 $13.7 Million
Q4 2022

Feb 13, 2023

SELL
$11.1 - $18.26 $1.63 Million - $2.69 Million
-147,293 Reduced 11.78%
1,103,055 $14.5 Million
Q3 2022

Nov 14, 2022

BUY
$10.82 - $16.84 $454,375 - $707,178
41,994 Added 3.48%
1,250,348 $16.9 Million
Q2 2022

Aug 12, 2022

BUY
$9.52 - $15.65 $443,946 - $729,806
46,633 Added 4.01%
1,208,354 $14.8 Million
Q1 2022

May 12, 2022

BUY
$13.24 - $20.24 $2.03 Million - $3.11 Million
153,460 Added 15.22%
1,161,721 $16.7 Million
Q4 2021

Feb 10, 2022

BUY
$15.44 - $27.32 $3.19 Million - $5.64 Million
206,483 Added 25.75%
1,008,261 $19.9 Million
Q3 2021

Nov 09, 2021

BUY
$20.7 - $34.69 $14.3 Million - $24 Million
691,831 Added 629.24%
801,778 $17.3 Million
Q2 2021

Aug 11, 2021

BUY
$18.58 - $25.37 $2.04 Million - $2.79 Million
109,947 New
109,947 $2.74 Million

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.36B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.